Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Declines By 51.2%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 7,266 shares, a decrease of 51.2% from the April 15th total of 14,880 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 16,053 shares, the short-interest ratio is presently 0.5 days.

Xenetic Biosciences Price Performance

Shares of XBIO opened at $3.04 on Friday. Xenetic Biosciences has a one year low of $1.90 and a one year high of $13.93. The firm has a market capitalization of $6.96 million, a P/E ratio of -2.53 and a beta of 2.20. The business has a fifty day moving average of $3.02 and a 200 day moving average of $2.63.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The firm had revenue of $0.81 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Xenetic Biosciences has an average rating of “Sell”.

Institutional Trading of Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC acquired a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.